Breast Cancer Cells Winston Salem NC

Breast cancer patients with isolated tumor cells or tiny "micrometastases" in the lymph nodes benefit from adjuvant treatment, such as post-surgical chemotherapy or hormonal therapy, a new study finds.

Debra Renee Tegeler, MD
Winston Salem, NC
Specialties
Internal Medicine, Medical Oncology
Gender
Female
Education
Medical School: Univ Of Mo-Kansas City Sch Of Med, Kansas City Mo 64108
Graduation Year: 1984

Data Provided by:
Susan Jean Hines, MD
(336) 277-8800
1010 Bethesda Ct
Winston Salem, NC
Specialties
Oncology (Cancer)
Gender
Female
Education
Medical School: Univ Of Cincinnati Coll Of Med, Cincinnati Oh 45267
Graduation Year: 1987

Data Provided by:
Dr.Rolland Barrett
(336) 277-8800
1010 Bethesda Ct
Winston Salem, NC
Gender
M
Speciality
Oncologist
General Information
Accepting New Patients: Yes
RateMD Rating
5.0, out of 5 based on 1, reviews.

Data Provided by:
Eugene H Paschold, MD
(336) 277-8800
1010 Bethesda Ct
Winston Salem, NC
Specialties
Oncology (Cancer), Internal Medicine
Gender
Male
Education
Medical School: Bowman Gray Sch Of Med Of Wake Forest Univ, Winston-Salem Nc 27157
Graduation Year: 1978
Hospital
Hospital: Wilkes Reg Med Ctr, N Wilkesboro, Nc
Group Practice: Piedmont Hematology Oncology Associates

Data Provided by:
Miles Robert Cooper, MD
(336) 777-3051
Medicine Center Boulevard,
Winston Salem, NC
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Bowman Gray Sch Of Med Of Wake Forest Univ, Winston-Salem Nc 27157
Graduation Year: 1962

Data Provided by:
Richard Alan Brodkin, MD
(336) 277-8800
1010 Bethesda Ct
Winston Salem, NC
Specialties
Oncology (Cancer), Hematology-Internal Medicine
Gender
Male
Education
Medical School: Bowman Gray Sch Of Med Of Wake Forest Univ, Winston-Salem Nc 27157
Graduation Year: 1974
Hospital
Hospital: Forsyth Mem Hosp, Winston Salem, Nc
Group Practice: Piedmont Hematology Oncology Associates

Data Provided by:
Hugh James Wallace, MD
(336) 277-8800
1010 Bethesda Ct
Winston Salem, NC
Specialties
Oncology (Cancer), Internal Medicine
Gender
Male
Education
Medical School: Va Commonwealth Univ, Med Coll Of Va Sch Of Med, Richmond Va 23298
Graduation Year: 1989
Hospital
Hospital: Forsyth Mem Hosp, Winston Salem, Nc; Medical Park Hospital, Winston Salem, Nc; Comm Gen Hosp Of Thomasville, Thomasville, Nc; Wilkes Reg Med Ctr, N Wilkesboro, Nc
Group Practice: Piedmont Hematology Oncology Associates

Data Provided by:
Mebea Aklilu
(336) 716-2255
Medical Center Blvd
Winston-Salem, NC
Specialty
Hematology / Oncology, Medical Oncology

Data Provided by:
Susan Anitra Melin, MD
(336) 716-7975
Medical Center Blvd,
Winston Salem, NC
Specialties
Oncology (Cancer)
Gender
Female
Education
Medical School: Bowman Gray Sch Of Med Of Wake Forest Univ, Winston-Salem Nc 27157
Graduation Year: 1985

Data Provided by:
Steven Alan Akman, MD
(336) 716-0230
Medical Center Blvd,
Winston Salem, NC
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: A Einstein Coll Of Med Of Yeshiva Univ, Bronx Ny 10461
Graduation Year: 1975

Data Provided by:
Data Provided by:

Breast Cancer Cells

Provided By:

Breast cancer patients with isolated tumor cells or tiny "micrometastases" in the lymph nodes benefit from adjuvant treatment, such as post-surgical chemotherapy or hormonal therapy, a new study finds.

Until now, many doctors doubted that the presence of micrometastases or isolated tumor cells affected long-term recovery, said Dr. Vivianne Tjan-Heijnen, head of the division of medical oncology at Maastricht University Medical Center in the Netherlands, the lead author of the study.

So these patients often are not offered adjuvant therapy after they undergo breast cancer surgery. But the results of her team's study, published in the Aug. 13 issue of the New England Journal of Medicine, suggest they should be.

Micrometastases, which are too small to be seen on standard screening or diagnostic tests, range from 0.2 to 2.0 millimeters in size. Isolated tumor cells or tumor cell groups are even tinier, less than 0.2 millimeters, said Tjan-Heijnen.

To assess the value of additional treatments of chemo or other adjuvant methods, Tjan-Heijnen and her colleagues followed 2,707 women treated surgically for early-stage breast cancer. They were divided into three groups. The first group included 856 women diagnosed with breast cancer whose sentinel node -- the first node the breast tissue drains into -- was negative and cancer-cell free, who didn't get additional treatment. The second group included 856 women diagnosed with breast cancer with cancer cells found in the nodes, but who didn't get additional treatment. The third group included 995 patients with cancer cells found in the nodes who did get additional treatment.

The additional treatment included chemotherapy (such as taxanes), endocrine therapy (such as tamoxifen or aromatase inhibitors), or systemic therapy (both chemo and endocrine).

The researchers followed the women for a median of 5.1 years (half followed longer, and half for less time) to see if the extra therapy reduced cancer recurrence and increased disease-free survival. They associated the tiny metastases and isolated tumor cells with an absolute decline in five-year disease-free survival of 10 percent. In other words, those with the tiny cancer cells present who are treated with additional therapy had a nearly 10 percent improvement in disease-free survival at five years, they found.

"So, five years after the diagnosis of every 100 patients with micrometastases or isolated tumor cells, 10 more will have a disease event compared with 100 patients with comparable primary tumor characteristics who did not have metastases in the axillary nodes," Tjan-Heijnen said.

The study proves that the micrometastases and the isolated tumor cells are important considerations when evaluating the prognosis, she said.

Cancer specialists have debated how to treat a patient with these small metastases and isolated tumor cells, said Dr. Minetta Liu, director of translational breast cancer research at the Georgetown University Lombardi Comprehensive Cancer Center in Washington, D.C.

The study results suggest that "looking for these cells may be another tool to determine how likely a recurrence is," she said. But more study is needed to validate the findings, she added.

Dr. Hannah Linden, a medical oncologist and associate professor of medicine at the University of Washington School of Medicine in Seattle, said the study results could change current practice. "If these findings are true, they will influence decision making significantly, and help us know which patients really 'need' chemo to give them an advantage in reducing the risk that the tumor recurs," she said.

More information

To learn more about adjuvant therapy for breast cancer, visit the U.S. National Cancer Institute.

SOURCES: Vivianne Tjan-Heijnen, M.D., Ph.D., head of medical oncology division, Maastricht University Medical Center, the Netherlands; Minetta Liu, director of translational breast cancer research, Georgetown University Lombardi Comprehensive Cancer Center, Washington, D.C.; Hannah Linden, M.D., medical oncologist and associate professor of medicine, University of Washington School of Medicine, and joint associate member, Fred Hutchinson Cancer Research Center, Seattle; Aug. 13, 2009, The New England Journal of Medicine

Author: By Kathleen Doheny
HealthDay Reporter

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com